Entresto (sacubitril/valsartan)

pCPA File Number: 21558

Negotiation Status:

Concluded with an LOI

Indication(s):

Heart failure, NYHA class II or III

Sponsor/Manufacturer:

Novartis Pharmaceuticals Canada Inc.

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2021-08-20

Negotiation Process Concluded:

2022-08-17